{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T07:13:05Z","timestamp":1693638785883},"reference-count":35,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revue des Maladies Respiratoires"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.rmr.2017.09.007","type":"journal-article","created":{"date-parts":[[2018,2,17]],"date-time":"2018-02-17T13:31:37Z","timestamp":1518874297000},"page":"149-159","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["C\u00e9l\u00e9coxib, une alternative s\u00fbre pour les syndromes de Fernand Widal\u00a0?"],"prefix":"10.1016","volume":"35","author":[{"given":"A.","family":"Schaller","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Metz-Favre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Guenard-Bilbaut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"De Blay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.rmr.2017.09.007_bib0180","doi-asserted-by":"crossref","first-page":"373","DOI":"10.2500\/108854193778774065","article-title":"Anaphylaxie et idiosyncrasie","volume":"14","author":"Widal","year":"1993","journal-title":"Allergy Proc"},{"key":"10.1016\/j.rmr.2017.09.007_bib0185","doi-asserted-by":"crossref","first-page":"975","DOI":"10.7326\/0003-4819-68-5-975","article-title":"Intolerance to aspirin. Clinical studies and consideration of its pathogenesis","volume":"68","author":"Samter","year":"1968","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.rmr.2017.09.007_bib0190","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/0021-8707(67)90076-7","article-title":"Concerning the nature of intolerance to aspirin","volume":"40","author":"Samter","year":"1967","journal-title":"J Allergy"},{"key":"10.1016\/j.rmr.2017.09.007_bib0195","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.jaci.2006.07.024","article-title":"Clinical and pathologic perspectives on aspirin sensitivity and asthma","volume":"118","author":"Stevenson","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.rmr.2017.09.007_bib0200","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1136\/bmj.328.7437.434","article-title":"Systematic review of prevalence of aspirin induced asthma and its implications for clinical practice","volume":"328","author":"Jenkins","year":"2004","journal-title":"BMJ"},{"key":"10.1016\/j.rmr.2017.09.007_bib0205","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.jaci.2014.08.020","article-title":"Prevalence of aspirin-exacerbated respiratory disease among asthmatic patients: a meta-analysis of the literature","volume":"135","author":"Rajan","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.rmr.2017.09.007_bib0210","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1034\/j.1399-3003.2000.016003432.x","article-title":"Natural history of aspirin-induced asthma. AIANE investigators. European Network on aspirin-induced asthma","volume":"16","author":"Szczeklik","year":"2000","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2017.09.007_bib0215","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1164\/ajrccm\/144.6.1411","article-title":"Urinary leukotriene E4\u00a0levels after allergen and exercise challenge in bronchial asthma","volume":"144","author":"Smith","year":"1991","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.rmr.2017.09.007_bib0220","first-page":"308","article-title":"Practical guidelines for diagnosing hypersensitivity reactions to nonsteroidal anti-inflammatory drugs","volume":"24","author":"Ortega","year":"2014","journal-title":"J Investig Allergol Clin Immunol"},{"key":"10.1016\/j.rmr.2017.09.007_bib0225","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1136\/bmj.1.5949.67","article-title":"Relationship of inhibition of prostaglandin biosynthesis by analgesics to asthma attacks in aspirin-sensitive patients","volume":"1","author":"Szczeklik","year":"1975","journal-title":"Br Med J"},{"key":"10.1016\/j.rmr.2017.09.007_bib0230","doi-asserted-by":"crossref","first-page":"S142","DOI":"10.1164\/ajrccm.161.supplement_1.ltta-28","article-title":"Genetic mechanisms in aspirin-induced asthma","volume":"161","author":"Szczeklik","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2017.09.007_bib0235","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S1081-1206(10)62221-1","article-title":"Classification of allergic and pseudoallergic reactions to drugs that inhibit cyclooxygenase enzymes","volume":"87","author":"Stevenson","year":"2001","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.rmr.2017.09.007_bib0240","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1183\/09031936.93.03050588","article-title":"The cyclooxygenase theory of aspirin-induced asthma","volume":"3","author":"Szczeklik","year":"1990","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2017.09.007_bib0245","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1067\/mai.2003.1450","article-title":"Biochemical and clinical evidence that aspirin-intolerant asthmatic subjects tolerate the cyclooxygenase 2-selective analgetic drug celecoxib","volume":"111","author":"Gyllfors","year":"2003","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.rmr.2017.09.007_bib0250","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1002\/art.10426","article-title":"The safety of celecoxib in patients with aspirin-sensitive asthma","volume":"46","author":"Woessner","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rmr.2017.09.007_bib0255","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S1081-1206(10)61392-0","article-title":"Safety of high-dose rofecoxib in patients with aspirin-exacerbated respiratory disease","volume":"93","author":"Woessner","year":"2004","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.rmr.2017.09.007_bib0260","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/2045-7022-3-20","article-title":"Tolerance to alternative cyclooxygenase-2\u00a0inhibitors in nonsteroidal anti-inflammatory drug hypersensitive patients","volume":"3","author":"Malskat","year":"2013","journal-title":"Clin Transl Allergy"},{"key":"10.1016\/j.rmr.2017.09.007_bib0265","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0140-6736(98)12154-2","article-title":"COX-2\u00a0inhibitors","volume":"353","author":"Hawkey","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.rmr.2017.09.007_bib0270","doi-asserted-by":"crossref","first-page":"7563","DOI":"10.1073\/pnas.96.13.7563","article-title":"Nonsteroid drug selectivities for cyclo-oxygenase-1\u00a0rather than cyclo-oxygenase-2\u00a0are associated with human gastrointestinal toxicity: a full in vitro analysis","volume":"96","author":"Warner","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.rmr.2017.09.007_bib0275","doi-asserted-by":"crossref","first-page":"3","DOI":"10.4168\/aair.2011.3.1.3","article-title":"Aspirin-exacerbated respiratory disease: evaluation and management","volume":"3","author":"Lee","year":"2011","journal-title":"Allergy Asthma Immunol Res"},{"key":"10.1016\/j.rmr.2017.09.007_bib0280","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1067\/mai.2001.116290","article-title":"Lack of cross-reactivity between rofecoxib and aspirin in aspirin-sensitive patients with asthma","volume":"108","author":"Stevenson","year":"2001","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.rmr.2017.09.007_bib0285","first-page":"323","article-title":"Les conditions de s\u00e9curit\u00e9 pour la r\u00e9alisation des tests de provocation en allergologie","volume":"47","author":"Bousquet","year":"2007","journal-title":"Rev Fr Allergol Immunol Clin"},{"key":"10.1016\/j.rmr.2017.09.007_bib0290","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.jaci.2012.08.023","article-title":"The Asthma Control Test and Asthma Control Questionnaire for assessing asthma control: systematic review and meta-analysis","volume":"131","author":"Jia","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.rmr.2017.09.007_bib0295","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJM200101113440215","article-title":"Celecoxib in patients with asthma and aspirin intolerance. The Celecoxib in Aspirin-Intolerant Asthma Study Group","volume":"344","author":"Dahlen","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmr.2017.09.007_bib0300","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1067\/mai.2000.110926","article-title":"Selective cyclo-oxygenase 2\u00a0inhibitor in patients with aspirin-induced asthma","volume":"106","author":"Yoshida","year":"2000","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.rmr.2017.09.007_bib0305","first-page":"75","article-title":"Asthmatic reaction induced by celecoxib in a patient with aspirin-induced asthma","volume":"19","author":"Munoz-Cano","year":"2009","journal-title":"J Investig Allergol Clin Immunol"},{"key":"10.1016\/j.rmr.2017.09.007_bib0310","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.jaci.2008.09.048","article-title":"Rational approach to aspirin dosing during oral challenges and desensitization of patients with aspirin-exacerbated respiratory disease","volume":"123","author":"Hope","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.rmr.2017.09.007_bib0315","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2500\/aap.2011.32.3413","article-title":"Selective cyclooxygenase-2\u00a0inhibitor cross-reactivity in aspirin-exacerbated respiratory disease","volume":"32","author":"Umemoto","year":"2011","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.rmr.2017.09.007_bib0320","first-page":"275","article-title":"Tolerability to etoricoxib in patients with aspirin-exacerbated respiratory disease","volume":"23","author":"Koschel","year":"2013","journal-title":"J Investig Allergol Clin Immunol"},{"key":"10.1016\/j.rmr.2017.09.007_bib0325","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.jaci.2005.10.021","article-title":"Asthma attacks induced by low doses of celecoxib, aspirin, and acetaminophen","volume":"117","author":"Baldassarre","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.rmr.2017.09.007_bib0330","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.jaci.2006.06.028","article-title":"Different eicosanoid profile of the hypersensitivity reactions triggered by aspirin and celecoxib in a patient with sinusitis, asthma, and urticaria","volume":"118","author":"Mastalerz","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.rmr.2017.09.007_bib0335","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s00403-007-0757-6","article-title":"Tolerance to coxibs in patients with intolerance to non-steroidal anti-inflammatory drugs (NSAIDs): a systematic structured review of the literature","volume":"299","author":"Weberschock","year":"2007","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.rmr.2017.09.007_bib0340","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1385\/CRIAI:24:2:137","article-title":"Anaphylactic and anaphylactoid reactions to aspirin and nonsteroidal anti-inflammatory drugs","volume":"24","author":"Stevenson","year":"2003","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.rmr.2017.09.007_bib0345","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/S1081-1206(10)62327-7","article-title":"Anaphylaxis to celecoxib","volume":"87","author":"Levy","year":"2001","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.rmr.2017.09.007_bib0350","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1034\/j.1398-9995.2002.1n3581.x","article-title":"Anaphylaxis to celecoxib","volume":"57","author":"Grob","year":"2002","journal-title":"Allergy"}],"container-title":["Revue des Maladies Respiratoires"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0761842517310203?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0761842517310203?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T02:28:58Z","timestamp":1693535338000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0761842517310203"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["S0761842517310203"],"URL":"https:\/\/doi.org\/10.1016\/j.rmr.2017.09.007","relation":{},"ISSN":["0761-8425"],"issn-type":[{"value":"0761-8425","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"C\u00e9l\u00e9coxib, une alternative s\u00fbre pour les syndromes de Fernand Widal\u00a0?","name":"articletitle","label":"Article Title"},{"value":"Revue des Maladies Respiratoires","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmr.2017.09.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 SPLF. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}